BlackRock Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

BlackRock Group’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.13M	Buy	+74,653	New	+$1.01M	﹤0.01%	2078

Other funds holding RARX

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlackRock Group's RARX Position: Q4 2016 in Review

BlackRock Group opened a new position in Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2016: 74,653 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #2078 among its holdings.

59 funds tracked by Wall St. Rank hold RARX as of Q4 2016.

BlackRock Group held 74,653 shares of Ra Pharmaceuticals, Inc. Common Stock worth $1.13M as of Q4 2016.
Ra Pharmaceuticals, Inc. Common Stock was a new BlackRock Group position in Q4 2016.
Ra Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2078 holding.
59 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.